Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
Finance
Page 4
Finance
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
UK unveils funding for AI companies to transform cancer care and spark new drug breakthroughs
Bain Capital to acquire Mitsubishi Tanabe Pharma Corporation
Novartis bolsters late-stage cardiovascular pipeline with acquisition of Anthos Therapeutics
University spinout secures funding to advance healthcare diagnostics
UCB to divest mature neurology and allergy business in China
28th August 2024
Accenture invests in Earli Inc. to advance technologies for early cancer...
27th August 2024
Baxter to divest Vantive Kidney Care segment to Carlyle for $3.8bn
16th August 2024
MSD to acquire investigational B-cell depletion therapy
12th August 2024
Calibre Scientific acquires provider of laboratory consumables and equipment, ACEFESA
8th August 2024
Clinigen acquires Kinesys Consulting to boost regulatory affairs expertise
7th August 2024
Otsuka Pharmaceutical to acquire Jnana Therapeutics
6th August 2024
Collegium expands into neurology with Ironshore Therapeutics acquisition
31st July 2024
Boehringer Ingelheim acquires Nerio Therapeutics
30th July 2024
Agilent to acquire BIOVECTRA
29th July 2024
1
...
3
4
5
...
33
Page 4 of 33
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...